These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

494 related items for PubMed ID: 16076267

  • 1. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ, Lip GY.
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY.
    Pathophysiol Haemost Thromb; 2005 Jul; 34 Suppl 1():25-30. PubMed ID: 15812201
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL.
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ximelagatran: a new oral anticoagulant.
    Hrebickova L, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Mar; 5(6):397-408. PubMed ID: 14633322
    [Abstract] [Full Text] [Related]

  • 9. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL.
    Rev Cardiovasc Med; 2004 Mar; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [Abstract] [Full Text] [Related]

  • 10. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006 Mar; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 11. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD, Arneklev K, Goldhaber SZ, Spandorfer J, Halperin F, Horrow J.
    Arch Intern Med; 2006 Apr 24; 166(8):853-9. PubMed ID: 16636210
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C, Singh BN.
    Minerva Cardioangiol; 2004 Apr 24; 52(2):125-39. PubMed ID: 15194994
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.